Tech Company Financing Transactions
RareCyte Funding Round
RareCyte closed a financing round on 8/22/2012. Investors included Telegraph Hill Partners and private investors.
Transaction Overview
Company Name
Announced On
8/22/2012
Transaction Type
Venture Equity
Amount
Unknown
Round
Undisclosed
Investors
Telegraph Hill Partners (Lead Investor) (Robert Shepler)
Proceeds Purpose
RareCyte plans to use the funds to complete the final stages of product development and initiate the platform's commercial launch in the research oncology market.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
2601 4th Ave.
Seattle, WA 98121
USA
Seattle, WA 98121
USA
Phone
Website
Email Address
Overview
RareCyte is a life science research and diagnostic development company focused on characterizing and isolating rare cells in the blood. Our team of biologists and engineers is dedicated to building innovative technologies to better understand human health and disease.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Joe Victor
Chief Medical Officer
Eric Kaldjian
VP - Bus. Development
Leighton Howells
VP - Engineering
Steve Reese
VP - Finance
James Cooper
VP - Operations
Tony Dedeo
VP - Product Management
Josh Nordberg
VP - R & D
Tad George
Browse more venture capital transactions:
Prev: 8/22/2012: Ginger Software venture capital transaction
Next: 8/22/2012: FutureAdvisor venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to report on every notable VC transaction. All VC database entries reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs